NCT01767701View on ClinicalTrials.gov

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

Raltegravir

400mg twice daily for 3 months

Trial Locations (1)

E1 2AT

The Royal London Hospital, London

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Queen Mary University of London

OTHER

NCT01767701 - Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis | Biotech Hunter | Biotech Hunter